Last reviewed 2026-04-20 · How we verify

A2B395

A2 Biotherapeutics Inc. · Phase 1 active Biologic Quality 0/100

At a glance

Generic name	A2B395
Also known as	Tmod CAR T-cell Therapy
Sponsor	A2 Biotherapeutics Inc.
Modality	Biologic
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results